Exploiting RhoA Mutations in Diffuse Gastric Adenocarcinoma and Targeting Intertwined RhoA and Yap1 Pathways for Therapeutic Advantage

Abstract

Our IDEA is on the right track. We have successfully inserted a fluorescent marker mOrange into MITs Dr. Zhang's pLenti-Crispr-v2, making transfection into mammalian cells easier and visible under fluorescent microscope, it the same time, those cells under Crispr editing are also selectable with puromycin. We have successfully knocked-out RhoA expression in cell lines of AGS and GT5.With RhoA knockout in cell line GT5, Yap1 is also significantly downregulated. Reintroducing mutant RhoA-Y42C is in progress.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Oct 01, 2017
Accession Number
AD1046138

Entities

People

  • Jaffer Ajani

Organizations

  • University of Texas at Austin

Tags

DTIC Thesaurus Topics

  • Adenocarcinoma
  • Biomedical Research
  • Cancer
  • Cell Line
  • Cells
  • Clinical Trials
  • Department Of Defense
  • Gene Expression
  • Genetics
  • Medical Personnel
  • Mutations
  • Neoplasms
  • Patent Applications
  • Professional Development
  • Targeting
  • Therapy
  • Training

Fields of Study

  • Biology

Readers

  • Computer Vision.
  • Forest Ecology
  • Molecular Genetics

Technology Areas

  • Biotechnology